22UA:FRA
BioNTech SE - ADR
79,60 €
arrow_upward
+0,63%(+0,50) 1D
15 ოქტ, 22:00:00 GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 22UA...
Open
78,65 €
High
79,70 €
Low
78,60 €
Mkt. cap
22,66 მლრდ.
Avg. vol.
1,41 ათ.
Volume
52,00
52-wk high
105,50 €
52-wk low
68,00 €
No. of employees
8 ათ.
Open
78,65 €
High
79,70 €
Low
78,60 €
Mkt. cap
22,66 მლრდ.
Avg. vol.
1,41 ათ.
Volume
52,00
52-wk high
105,50 €
52-wk low
68,00 €
No. of employees
8 ათ.
News stories
From web sources and news partners
ad-hoc-news.de
·
3 საათის წინ
Canaccord cuts target for BioNTech stock to USD 132.00
Pluang
·
1 დღის წინ
BioNTech shares drop 7.13% after trial failure raises concerns over oncology program claims
Simply Wall Street
·
1 დღის წინ
BioNTech Stock Faces Questions After Cancer Trial Missed Progression Free Survival Goal
TradingKey
·
2 დღის წინ
Biontech SE Stock (BNTX) Closed Down by 7.13% on Oct 13: Drivers Behind the Movement
Profile
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
About BioNTech SE - ADR